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SUMMARY. Pregnancy is a para-physiologic condition,
which usually evolves without any complications in the
majority of women, even if in some circumstances moder-
ate or severe clinical problems can also occur. Among
complications occurring during the second and the third
trimester very important are those considered as concur-
rent to pregnancy such as hyperemesis gravidarum, intra-
hepatic cholestasis of pregnancy, HELLP syndrome and
acute fatty liver of pregnancy. The liver diseases concur-
rent to pregnancy typically occur at specific times during
the gestation and they may lead to significant maternal
and foetal morbidity and mortality. Commonly, delivery of
the foetus, even preterm, usually terminates the progres-
sion of these disorders. All chronic liver diseases, such as
chronic viral hepatitis, autoimmune hepatitis, Wilson’s dis-
ease, and cirrhosis of different aetiologies may cause liver
damage, independently from pregnancy. In this review we
will also comment the clinical implications of pregnancies
occurring in women who received a orthotopic liver trans-
plantation (OLT) Therefore, the management of immuno-
suppressive therapy before and after the delivery in women
who received liver transplant is becoming a relevant clini-
cal issue. Finally, we will focus on acute and chronic viral
hepatitis occurring during pregnancy, on management of
advanced liver disease and we will review the literature on
the challenging issue regarding pregnancy and OLT. 2
Keywords: anti-viral therapy 3, liver disease, liver transplant,
pregnancy.
INTRODUCTION4
Pregnancy is a paraphysiologic condition, which usually
evolves without any complications in the majority of
women, even if in some circumstances moderate or severe
clinical problems can also occur. Concerning the complica-
tions occurring during the second and the third trimester
of pregnancy, a peculiar attention should be paid to those
involving the liver, commonly referred as concurrent to
pregnancy. Among these, we can found liver diseases
unique to pregnancy, such as hyperemesis gravidarum, int-
rahepatic cholestasis of pregnancy, HELLP syndrome and
acute fatty liver of pregnancy [1,2]. However, the majority
of liver disease pre-exist to pregnancy (Table 1) [1].
The liver diseases concurrent to pregnancy typically
occur at specific times during the gestation and they may
lead to significant maternal and foetal morbidity and mor-
tality. Usually, most of the drugs are forbidden in preg-
nancy, due to their teratogenicity, but the risks and
benefits of their use must be considered case by case. Com-
monly, delivery of the foetus, even preterm, usually termi-
nates the progression of these disorders [2].
All chronic liver diseases, such as chronic viral hepatitis,
autoimmune hepatitis, Wilson’s disease and cirrhosis of dif-
ferent aetiologies may cause liver damage, independently
from pregnancy [3]. On the other hand, the first group is
comprehensive of liver diseases that can occur during preg-
nancy, but not expressly related to it (such as acute viral
hepatitis sustained by both major and minor hepatotropic
virus) [3]. Furthermore, in this review, we will also com-
ment the clinical implications of pregnancies occurring in
women who received a orthotopic liver transplantation
(OLT) [4]. In fact, it has recently been reported a signifi-
cant increase of women that become pregnant after OLT.
In United States, more than 3000 females of childbearing
age have undergone OLT. Therefore, the management of
immunosuppressive therapy before and after the delivery
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in women who received liver transplant is becoming a rele-
vant clinical issue [4].
In our review, we will focus on acute and chronic viral
hepatitis occurring during pregnancy, on management of
advanced liver disease and we will review the literature on
the challenging issue regarding pregnancy and OLT.
ACUTE VIRAL HEPATITIS
Acute viral hepatitis can be acquired during pregnancy
(concurrent disease). If we refer only to hepatotropic
viruses, the incidence during of pregnancy is almost the
same as compared to the general population. Less common
during pregnancy is the occurrence of viral hepatitis due
to nonhepatotropic viruses.
Acute viral hepatitis is responsible of most of cases of
jaundice in pregnant women [1]. In the majority of cases,
the clinical course is benign but sometimes cholestasis is
manifest and can be prolonged up to puerperium. The
major concern is the risk of infection to the foetus (vertical
transmission). There is no clear evidence of teratogenic
effect of hepatitis viruses in the first trimester [2]. Acute
hepatitis acquired during pregnancy does not involve the
risk of foetal congenital anomalies, except for Cytomegalo-
virus (CMV) infection, and the only complication is related
to an increase of preterm delivery [2].
Nonhepatotropic viruses
Cytomegalovirus
Cytomegalovirus infection, which usually evolves asymp-
tomatically, has a high risk of vertical transmission and is
responsible for major foetal abnormalities (Table 2) [5].
Commonly, pregnancy is not affected by the clinical course
of infection, which is indolent in immunocompetent
subjects [5]. Laboratory serological tests are the main clues
to diagnose the CMV infection. Prevention is difficult
because the virus is ubiquitous and the contact is frequent.
Although controversial, some practices might minimize the
risk for congenital infection [5]. The saliva and urine of
infected children are significant sources of CMV infection.
Preventive measures such as frequent hand washing,
avoiding to share drinking glasses or eating with utensils
of young children, and further stay away from them
(avoiding kissing mouth or cheek) appear to be generally
acceptable [5,6].
Now, no therapeutic options during pregnancy are
available. Recent data obtained from literature have
focused the efficacy of preventive administration of CMV
immunoglobulins or antiviral drugs (Valacyclovir) to preg-
nant women with primary CMV infection to reduce the
rate of vertical transmission and improve neonatal out-
come [7]. The risk of mother-to-foetus transmission is
higher when infection is acquired in the first trimester. On
the contrary, risk of foetal damages is higher for infections
acquired during the last trimester. For this reason, CMV
seronegative women must be screened along the preg-
nancy with serological tests. CMV infection of the mother
does not involve any risk. No therapeutic options aimed to
protect the foetus are available for women infected during
pregnancy, but new strategies are still ongoing. Until
now, the only option to evaluate together with the mother
in case of foetal infection is the termination of pregnancy,
considering the high probability of foetal abnormalities
[7].
Herpes simplex virus
Herpes simplex virus (HSV) infection is rare, but potentially
lethal because it may cause fulminant hepatitis, with acute
liver failure, especially if it occurs in the third trimester.
The rate of mortality in untreated individuals is more than
80% [8]. Moreover, the hepatitis is anicteric in 90% of
cases, so that the clinical suspicion arises in mostly asymp-
tomatic patients with elevated transaminases (more than 3
times u.l.n.) and normal or mildly elevated bilirubin, often
without the typical mucocutaneous lesions [8,9]. Serologi-
cal tests to confirm diagnosis include HSV-IgM and HSV-
PCR. It has been shown that viral load and transaminases
levels are related to disease severity [9]. During pregnancy,
the seroconversion rate is about 2% of women susceptible
to HSV [9,10]. The serotypes that may cause of hepatitis
are HSV-1 and HSV-2 in both primary and latent infec-
tions [9].
The premature delivery is not indicated in these cases,
as the therapy with acyclovir or vidarabine is effective. The
treatment must be started immediately because is life sav-
ing for the mother and the foetus [9–11]. Acyclovir is a
nucleoside analogue antiviral agent, which is active, and it
is recommended for use only when the potential benefit
outweighs the potential risks to the foetus [12]. Moreover,
in the case of suspected herpes simplex dissemination and
Table 1 Liver diseases concurrent or related to pregnancy,
according to trimester of gestation and liver involvement
Pre-existing or
concurrent liver
disease
Viral Hepatitis
1. Acute (HAV, HBV, HCV,HEV, CMV,
HSV)
2. Chronic (HBV,HCV)
Autoimmune hepatitis
Wilson’s disease
Cirrhosis (different aetiology)
Pregnancy-related
diseases
1st Trimester:
Hyperemesis gravidarum
2nd Trimester:
Intrahepatic cholestasis of pregnancy
3rd Trimester:
Intrahepatic cholestasis of pregnancy
Eclampsia
HELLP syndrome
Acute fatty liver of pregnancy
© 2014 John Wiley & Sons Ltd
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hepatic failure, this therapeutic approach is mandatory
[9,11].
Hepatotropic viruses
Hepatitis A virus
Hepatitis A virus (HAV) can cause clinical complications if
it occurs during the second/third trimester of pregnancy.
Most of the cases are anicteric and usually mild; fulminant
hepatitis is rare [1]. It has been generally accepted that
pregnancy itself does not show a negative impact on the
course of hepatitis A infection. However, acute HAV hepa-
titis during pregnancy may be associated with a higher
risk of maternal complications and therefore early delivery
is indicated only in cases with severe liver dysfunction at
the third trimester of gestation [13]. In Western countries,
HAV is not frequent. However, in developing countries,
there is a high incidence of fulminant hepatitis, probably
favoured by a concomitant condition of malnutrition. In
serious cases, hospitalization is required especially when
nausea and vomiting are severe in the last quarter and
induction of premature labour may be occur. However,
commonly HAV hepatitis does not represent an indication
for Caesarean section, or early termination of pregnancy
[14]. Although intrauterine transmission is rare, it has
been described in the presence of high levels of viral load
at delivery [15]. When HAV infection is diagnosed in the
third trimester, the foetus must be protected against the
virus by administration of immune globulin within 48 h
before the birth. Breastfeeding is not contraindicated [16].
Hepatitis E virus
Hepatitis E virus (HEV) hepatitis is rare in Western countries,
but it is endemic in several areas of Africa, Asia and Central
America, where, if acquired during pregnancy, may show a
fulminant course with a mortality rate in one of six pregnan-
cies [17]. Although in Western countries this is not a
frequent occurrence, the HEV incidence is increased in
Europe as well, especially for genotype 3 [1]. A recent
French study has reported that 90% of acute hepatitis E
acquired in the indigenous route, so that it looks like that
current HEV epidemiology is going to change [17].
The severe clinical course of HEV infection in preg-
nancy differs among different Countries. It is conceivable
that malnutrition and poor social conditions are the
main co-factors promoting this evolution [18,19]. The
reason to explain the greater susceptibility to HEV infec-
tion in pregnant women is still not known. The hypoth-
esis of the reduced immunological activity and hormonal
factors could be considered [20]. Acute HEV infection
carries high mortality rates (15–25%) in pregnant
women, especially in the third trimester, in association
with acute liver failure, eclampsia and haemorrhages
[21]. This is very common in developing countries, due
to the emergence of genotype 3 [22]; the level of vire-
mia seems to be likely associated with the severity of
the disease during pregnancy [23]. The effect of acute
HEV infection on clinical course of pregnancy in Western
countries is still not known [22]. Vertical transmission
occurs in 50% of cases and the infection is always
symptomatic with high rates of morbidity (hepatitis, pre-
maturity, hypothermia and hypoglycaemia) and mortality
in the newborns [21].
No data are available on antiviral drugs for HEV. Treat-
ment is only supportive. There are some reports concern-
ing ribavirin-based treatment, but the teratogenic effect
excludes any potential use in pregnant women. In case of
life-threatening condition of the mother, termination of
pregnancy is the rule [20–22]. Researches to develop an
anti-HEV vaccine are underway [2,21].
Hepatitis B virus
All pregnant women are routinely tested for HBsAg at first
visit during gestation to screen hepatitis B virus (HBV)
infection. Acute HBV hepatitis is characterized by the
absence of clinical complications during the course of preg-
nancy, but it carries high risk of mother-to-foetus viral
transmission. This is particularly frequent if the mother is
HBeAg positive and has been infected during the third
trimester of gestation (50–80%), but the risk of transmis-
sion is lower when mother is anti-HBe positive (25%), or if
she is asymptomatic carrier (5%) [1]. The risk of transmis-
sion is very low in case of maternal infection during the
first or second trimester of pregnancy, but increases up to
50–70% if hepatitis occurs in the third trimester of preg-
nancy or soon after birth. The main risk factor for trans-
mission is the high viral load [24]. Consequently, antiviral
therapy during the third trimester has the goal to reduce
Table 2 Clinical features of acute hepatitis due to hepatotropic and nonhepatotropic viruses in pregnancy
CMV HSV HAV HBV HCV HEV
Latency Yes Yes No Yes No No
Symptoms Asymptomatic or
flu-likeYes, if
Potentially
lethal
Mild, rarely
lethal
Usually
asymptomatic
Usually
asymptomatic
Lethal
Foetal Abnormalities Contracted as primary
infectionYes
Yes, but rare No Yes rare,preterm
delivery
No No
Vertical transmission Yes Probable Yes Yes Yes
© 2014 John Wiley & Sons Ltd
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viremia and so lowering the risk of perinatal transmission
[24–26].
Both telbivudine and tenofovir can be taken to prevent
intrauterine and perinatal HBV transmission during the
last trimester of pregnancy in HBsAg-positive mother with
high levels of viremia (serum HBV-DNA ≥ 106 copies/mL)
but without significant ALT increase. The drug can be dis-
continued soon after the delivery if breastfeeding is planned
or within 3 months.
Infected newborns may become chronic HBsAg carriers
in 80–90% of cases together with subclinical hepatic dys-
function, although they rarely will develop neonatal hepati-
tis. Perinatal transmission can be prevented with the use of
anti-HBV vaccine and in association with hepatitis B immu-
noglobulin (HBIG) at birth with a percentage of success of
about 95%. Patients at high risk of infection can be immu-
nized before or during pregnancy by HBV vaccination
without any risk for the foetus [2,24]. As regard HBV/HDV
co-infection in pregnancy, there are very few data in
literature.
Hepatitis C virus
The frequency of acute hepatitis C virus (HCV) infection
during pregnancy is approximately calculated 0.4–6.0%
[1]. These percentages increase in groups at high risk of
infection (like anti-HIV positive, intravenous drug users).
HCV infection can be acquired during pregnancy, but it
does not affect the course of the pregnancy. The risk of
vertical transmission is very low (3–10%) and it is deter-
mined by the same risk factors of chronic hepatitis but no
therapy is available so far to avoid the contagion [27].
Routine screening is not recommended for HCV infection,
but it should be useful at least in ‘at risk’ groups to start
immediately after delivery the therapy [1]. Risk of vertical
transmission is higher during delivery, due to contamina-
tion with blood fluid, but it can also occur by transplacen-
tal crossing. After the delivery, maternal breastfeeding is
not absolutely contraindicated because risk of viral trans-
mission is very low during lactation and it is recommended
to pay attention to nipple abrasions [1,27] (http://www.
cdc.gov/breastfeeding/disease/hepatitis.htm5 ).
CHRONIC VIRAL HEPATITIS
Chronic viral hepatitis does not adversely affect the course
of pregnancy, but it carries the risk of vertical transmission
of the virus. Overall, chronic viral hepatitis is the most fre-
quent pre-existing liver disease and they need to be fol-
lowed through the whole period of pregnancy and overall
after delivery.
HBV infection
HBV is an important global health problem, because of
high risk of perinatal viral transmission. Before the adop-
tion of HBIG, approximately 70–90% of infants born to
HBeAg-positive mothers may became chronically infected
by HBV [26]. HBV infection does not significantly modify
the clinical course of pregnancy either fertility or concep-
tion unless the woman has liver cirrhosis or liver failure
[28–30]. Moreover, chronic HBV infection does not
increase maternal or foetal morbidity and mortality,
although a recent study has shown an increased risk of
diabetes mellitus, ante-partum haemorrhages and life-
threatening preterm labour [30]. On the other hand, in
the presence of cirrhosis, the risk to develop significant
perinatal complications and poor pregnancy outcome is
higher [31]. Moreover, cirrhotic pregnant women have
usually higher spontaneous rates of maternal complica-
tions such as placental abruption, gestational hypertension
and peripartum haemorrhages [1]. By the contrary, preg-
nancy does not influence the course of chronic HBV infec-
tion and usually it is not considered as a possible
worsening factor [24].
Nowadays, the risk of perinatal transmission, which rep-
resents in many areas of the world the primary source of
persistence of HBV chronic infection, has focused the atten-
tion to the management of HBV infection during preg-
nancy. The risk is very high in HBeAg-positive patients
with high viral load, but conflicting data exist about the
potential role of different HBV genotypes in influencing
transmission [24,32].
Among maternal risk factors affecting vertical or perina-
tal transmission, we also mention placental diseases or
complications appearing during labour and breastfeeding,
which is another major source of infection [24].
Together with the immunoprophylaxis, the choice of
correct antiviral therapy plays a major role in chronic
HBV-infected women. Not all available drugs for treatment
of chronic HBV infection can be used during pregnancy,
and they have an important role to avoid an exacerbation
of disease that can occur in case of drug discontinuation,
especially soon after the delivery, with high risk of occur-
rence of fulminant hepatitis causing a life-threatening con-
dition both for mother and foetus [1,25].
Drugs used for the treatment of chronic hepatitis B
(CHB) include recombinant interferon (IFN), pegylated
interferon (PEG-IFN) and Nucleos(t)ides analogues (NAs).
NAs are classified as nucleosides (lamivudine, telbivudine,
emtricitabine and entecavir) or nucleotides (adefovir and
tenofovir). All these drugs have been approved in Europe
for CHB treatment, while PEG-IFN and emtricitabine are
not licensed for HBV treatment in most European coun-
tries. Because of their possible teratogenicity, only drugs
classified in category C or B can be used during gestation.
According to FDA classification, lamivudine, entecavir and
adefovir are classified as ‘C’, while telbivudine and tenofo-
vir are classified as drugs of category B (Table 3). Until
now, the more appropriate drug is tenofovir because many
data are available about the safety profile in pregnancy.
© 2014 John Wiley & Sons Ltd
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Furthermore, several data above safety of tenofovir are
reported in HIV patients showing very low rate of congeni-
tal abnormalities [33]. By contrast, PEG-IFN is absolutely
contraindicated because of high teratogenicity risk. In fact,
women or partners of patients treated with PEG-IFN or in
childbearing age should use a good contraception system
until three to 6 months after stopping antiviral therapy
[34].
Regarding to the different pharmacological features and
teratogenicity risks of drugs for treating a young woman
chronically HBV infected that wish to become pregnant
should dispose her pregnancy and should be educated
about safety profile of drugs during pregnancy. According
to the last EASL guidelines, the therapeutic approach may
be different based on the severity of liver damage: in
women that want to become pregnant and do not have
an advanced fibrosis, it is advisable to delay therapy after
the delivery; in women with an advanced fibrosis or cir-
rhosis, therapy is mandatory [25]. During pregnancy, ther-
apy must be based on a NA of category B, possibly
tenofovir. If pregnancy is accidental and not planned, ther-
apy should be adjusted and modified with a NA of cate-
gory B [1].
HBV infection can be transmitted from mother-to-foetus
at delivery. This risk, as mentioned before, correlates with
viral load and HBeAg positivity. The prevention of HBV
perinatal transmission is traditionally based on the combi-
nation of passive and active immunization with HBIG and
HBV vaccination. Such a strategy, however, may not be
effective in a proportion of newborns from highly viremic
women (serum HBV-DNA >106–7 copies/mL), which carry
a risk of vertical HBV transmission more than 10% despite
administration of HBIG and vaccination. In these cases,
the use of NAs before delivery may reduce viral loads and
Table 3 Drugs for liver diseases and their use in women during pregnancy and after delivery
Class Drug
FDA
pregnancy
Effect on
conception Effect on foetus Breastfeeding
Antiviral drugs Acyclovir B Unknown No Unsafe
Boceprevir B No data No data No data
Entecavir C Unknown No data Unsafe
Lamivudine C Unknown No increases in birth
defects overall
Unsafe
Peg-IFN C Teratogenic Malformation Unsafe
Ribavirin X Teratogenic Teratogenic Unsafe
Telaprevir B No data No data Unsafe
Telbivudine B Unknown No adverse effects in
animals at doses as
high as 37 times
human dose
Possibly unsafe, excreted
into the milk of lactating rat
Tenofovir B Unknown No data Unsafe
Valacyclovir B Unknown No teratogenicity but
limited data
Unsafe
Diuretics Spironolactone C No Unknown Unsafe
Furosemide C No No Unknown
b-blockers Propranolol C Unknown IUGR, bradycardia,
hypoglycaemia, Distress
neonatal distress during
labour
Unknown
Nadolol C No Unknown Possible unsafe (mainly
at high dose)
Vasoactive
drugs
Vasopressin C Unknown Unknown Unknown
Immunosuppressive
drugs
Azathioprine D Unknown 22% malformations, 45%
first trimester abortion
Unsafe
Cyclosporine C Unknown Prematurity risk Unsafe
Tacrolimus C Probable Respiratory, renal
dysfunction, birth defects
Possible unsafe, very low
rate excreted in milk
Prednisone B No Very low rate of
malformation (4%)
Safe
Mycofenolate D Yes Birth defects Unknown
© 2014 John Wiley & Sons Ltd
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therefore improve the effectiveness of HBIG and vaccina-
tion [35].
Therapy with lamivudine and, more recently, with tel-
bivudine [36] during the last trimester in HBsAg-positive
women with high viral load has been shown to be safe
and to reduce the risk of intrauterine and perinatal trans-
mission of HBV if given in addition to passive and active
vaccination by HBIG and HBV vaccination after delivery.
No controlled clinical trial of tenofovir to prevent perinatal
transmission has been carried out until now.
There is not contraindication of breastfeeding for HBsAg-
positive mother, even if HBV-DNA has been found in
maternal milk [37]. No studies are available about safety
of NAs use during the breastfeeding. For mothers on antiv-
iral therapy with lamivudine or tenofovir, breastfeeding is
not recommended because few data are available about
the safety of antiviral exposure during breastfeeding
[33,37]; however, due to low oral bioavailability of tenofo-
vir in maternal milk, the newborn should not considered
to be at risk [33,38,39].
As regarding to HBV/HDV co-infection, clinical course of
HDV infection in pregnancy is similar in pregnant and
nonpregnant women, although the clinical suspicion of
this possible disease should arise in pregnant women with
acute or chronic hepatitis B with a reactivation or hyper-
transaminasemia, testing for anti-HDV. This is extremely
uncommon; however, because the vaccination for hepatitis
B, when given to newborns infants, is almost uniformly
effective against hepatitis D. Vertical transmission has not
been shown, so early delivery is not necessary. Breastfeed-
ing is safe, and vertical transmission can be avoided using
HBV immunoprophylaxis [38].
HCV infection
Prevalence of HCV infection in pregnant women ranges
between 1% and 2% in the United States and Europe, but
it could increase up to 8% in some developing countries.
HCV mother-to-child transmission (MTCT) has been clearly
documented, with reported rates of about 5–10% [1,40].
Pathogenesis of HCV infection in pregnancy and during
the neonatal period remains poorly understood. During
gestation, a modulation of immune responses differs
between the different stages of pregnancy [41,42]. In fact,
at the same time, the maternal immune system must
develop tolerance to paternal alloantigens to prevent
maternal immune aggression against the foetus and main-
tain active immunity against HCV to protect both mother
and foetus from the infection [41].
Although HCV affects a significant number of women
of reproductive age, few studies have examined the
impact of chronic HCV infection on pregnancy outcomes.
Pregnancy does not seem to adversely affect the clinical
course of HCV infection [43]. The majority of pregnant
anti-HCV-positive women are asymptomatic. It is possible
to observe during pregnancy a decrease of aminotransfe-
rases and an increase of HCV viral load, followed by an
inversion of parameters during the postpartum period
[1,43]. It has also been observed an increase of cases
with cholestasis of pregnancy in anti-HCV-positive women
[44]. The benign course of disease observed during preg-
nancy is attributed to the production of endogenous IFN
by foetus and placenta [45]. The ALT levels decrease in
association with viral load increase observed during the
third trimester of pregnancy in women chronically
infected by HCV could conceivably be explained by a
pregnancy-associated decline in immune-mediated hepato-
cellular destruction and change of immunological state
[40,46].
Multiple host factors have been shown to increase the
risk of HCV MTCT; some of them are unchangeable, such
as elevated viral load, co-infection with HIV, abuse of
drugs and alcohol, other are mainly related to delivery
management including amniocentesis and prolonged rup-
ture of membranes [42]. Viral transmission can occur both
in the uterus and during delivery. Indeed, perinatal HCV
transmission is almost restricted to women with detectable
HCV-RNA in the peripheral blood and MTCT rarely occurs
if the maternal viral load remains below 100 000 HCV-
RNA IU/mL [47]. However, there is a broad overlap in the
levels of plasma HCV-RNA between transmitting and non-
transmitting mothers [48].
The risk of vertical transmission is related to viral load.
Hence, the achievement of viral clearance would be desir-
able before pregnancy because there are no drugs for HCV
infection usable during gestation to reduce the risk of
transmission.
Women with HCV infection can plan a pregnancy, and
they must be educated about high teratogenicity risks of
therapy during pregnancy. HCV-infected women, treated
with standard therapeutic approach, must attend at least
6 months before becoming pregnant. If they accidentally
become pregnant, therapy must be stopped and the mother
should be informed for the risks of teratogenicity
[1,49,50].
HCV-infected pregnant women do not need special moni-
toring, but only prenatal routine care as noninfected preg-
nant women. Delivery modalities usually do not influence
vertical transmission, and Caesarean section is not consid-
ered a modality to prevent vertical transmission [43].
Data on transmission of HCV during lactation are con-
tradictory. It has been suggested a correlation between dis-
ease activity (raised transaminases and HCV-RNA positive)
and detection of HCV-RNA in breast milk resulting a
chance of increased disease transmission by this route
[42,49]. On the other hand, in several studies, transmis-
sion of HCV by breastfeeding has not been demonstrated,
so there are no specific contraindications of breastfeeding
in HCV-infected women [1,50]. Infected children can be
treated with the available options but usually they can be
© 2014 John Wiley & Sons Ltd
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treated only after the third year of age because of the
adverse effects of treatment on growth [51]. However,
spontaneous resolution of infection has been observed both
in mother during the postpartum period and in foetus
[45].
No data have been published about safety of boceprevir
and telaprevir in pregnant women. Their use is actually
contraindicated in patients taking oral contraceptive con-
taining ethinylestradiol and norethindrone so that alterna-
tive methods of nonhormonal contraception should be
used [52].
ADVANCED CHRONIC LIVER DISEASES
Advanced chronic liver diseases, irrespectively of their aeti-
ology, involve sexual dysfunctions with amenorrhoea and
infertility because of hormonal alterations [3,53]. In fact,
most women with decompensated cirrhosis are infertile
and have menstrual abnormalities, caused by hypotha-
lamic-pituitary dysfunction due to reduced level of gonado-
tropin-releasing hormone and reduced sex circulating
steroid hormones [2]. Moreover, when portosystemic
shunts are present, oestradiol and testosterone levels are
increased [1].
Once pregnancy has initiated, high risks for mother and
baby, such as prematurity, pulmonary hypertension, rup-
ture of varices and bleeding may occur. A study carried
out in a large cohort of pregnant women with cirrhosis
reported a rate of decompensation of 15% [54].
However, if liver function is in the normal range and
there is no clinically relevant portal hypertension, preg-
nancy can be carried out. Nevertheless, all these pregnan-
cies should be considered ‘at risk’, especially for the
mothers that can develop variceal bleeding, hepatic failure,
jaundice, thrombocytopenia and lineal aneurysm rupture
[55]. Foetal loss is also possible. The more dreadful compli-
cation is variceal bleeding (20–25%) [1], especially during
the second and third trimester when maternal blood vol-
ume is expanded and foetus and uterus dimension are
increased, causing compression on inferior cava vein and
collateral vessels [56]. For this reason, it is desirable to
check each patient at early second trimester with an upper
endoscopy and, in case of positive finding, to start prophy-
lactic treatment with beta-blockers [1]. If oesophageal vari-
ces are known before pregnancy, they should be treated
endoscopically by band ligation. In case of acute bleeding
during pregnancy, the approach is also endoscopic [57].
Use of vasopressin is contraindicated in pregnancy [1].
Sclerotherapy seems effective and safe for both, mother
and foetus. Variceal band ligation and butyl-cyanoacrylate
injection have been executed and resulted safe. Proprano-
lol, which is safe in pregnancy, may be a better option
once acute bleeding has been controlled [57]. Caesarean
section may reduce the risk of bleeding in patients with
large oesophageal varices, but it is not recommended as a
routine practice. If possible, a vaginal delivery is desirable
[1].
As regard to other sequelae related to cirrhosis (ascites,
spontaneous bacterial peritonitis, portosystemic encepha-
lopathy), they rarely occur during pregnancy. Ascites is a
very rare event; however, if necessary, depletive therapy is
based on sodium restriction and diuretics, as for nonpreg-
nant women with cirrhosis [28]. Hepatic encephalopathy
can be caused by particular conditions like hypoxia, infec-
tions and gastrointestinal haemorrhages; in these cases,
spinal and general anaesthesia during delivery should be
avoided for the risk of hypotension and worsening of
encephalopathy [28].
PREGNANCY AND LIVER TRANSPLANTATION
Pregnancy is a real opportunity for women recipients of
orthotopic liver transplantation (OLT). Although a success-
ful pregnancy is possible, it must be considered at risk.
Maternal and foetal complications can occur, such as pre-
eclampsia, hypertension, anaemia, renal dysfunction, dia-
betes, infections, prematurity, low weight at birth and mis-
carriage [2].
Obstetrical syndrome associated with OLT may depend by
several factors such as defective deep placentation, uterine
vascular bed and side effects of immunosuppressive therapy
on uteroplacental arteries, as reported in National Trans-
plantation Pregnancy Registry (NTPR), likewise immunosup-
pressive therapy can carry risk of miscarriage, prematurity,
intrauterine growth retardation and low birth rate [58].
Studies have been performed to compare clinical courses
of pregnancies in recipients of liver and renal transplanta-
tion, showing that outcomes of pregnancy after OLT are
better than those after renal transplantation [59].
Vaginal delivery is possible but, because of high incidence
of complications, the practice of Caesarean section is high,
about 40%. Similarly, as there is a high incidence of prema-
ture delivery, in particular due to significant risk of prema-
ture membrane rupture (40%), pregnancy course must be
closely monitored by a team of transplant hepatologists and
experienced obstetrics [2]. Female liver transplant recipients
who are planning a pregnancy should be adequately coun-
selled about the optimal timing of become pregnant, mode of
delivery and risks associated with immunosuppressive ther-
apy. Furthermore, they should also be recommended on
methods of contraception if pregnancy is not planned [59].
As clinical effect of immunosuppressive drugs reaches the
peak 1 year after transplant reducing the risk of allograft
rejection, it is advised to plan pregnancy about 18 months
up to 2 years after transplantation to minimize foetal expo-
sure to high doses of immunosuppressant drugs [2,59]. The
use of immunosuppressive therapy after liver transplanta-
tion is unavoidable. All immunosuppressive agents cross the
placenta and enter into foetal circulation with potentially
dangerous effects in utero. The 6immunosuppressive agents
© 2014 John Wiley & Sons Ltd
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such as azathioprine, cyclosporine and mycophenolic acid
have been shown to be teratogenic in animals. The risk of
birth defects is almost similar for all agents; some drugs, like
calcineurin inhibitors can lead to prematurity risk and oth-
ers (like cyclosporine) could have their effect on renal func-
tion increasing the risk of pre-eclampsia [58]. Tacrolimus
seems to give lower incidence of complications gaining a bet-
ter control of hepatic function [60]. Obviously, hepatic func-
tion must be strictly checked along the whole pregnancy
and every abnormalities should be managed in the same
way as in nonpregnant women [2].
As regard to breastfeeding mothers with OLT can safely
use prednisone or other glucocorticoids. The infant expo-
sure of tacrolimus with milk is very low, and therefore, its
administration may be compatible with breastfeeding. Data
collected from the NTPR indicate no adverse outcomes in
infants who were breastfed during maternal cyclosporine
use; insufficient evidence is present in the literature about
azathioprine’s teratogenicity [2]. Nevertheless, it is advised
to avoid breast feed in the first few months post-transplan-
tation where immunosuppressive therapy is at high serum
level.
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